Home > Boards > US OTC > Medical - Drugs >


Add AVXT Price Alert      Hide Sticky   Hide Intro
Moderator: johnny canuck, Rookiemove
Search This Board:
Last Post: 2/5/2016 11:07:58 PM - Followers: 35 - Board type: Free - Posts Today: 0


Industry Center - Biotechnology

Contact Information
Address: 2000 Hamilton St., Ste. 204
Philadelphia, PA 19130
Phone: 215-241-9760
Fax: 215-241-9684
Key People
CEO: Adele Sommerfeld
BOD: Andrew W. Dahl Sc.D.; Serge Morrell
AVAX Technologies wants to turn cancer cells into cancer fighters. The company is developing vaccines created by extracting a patient's own cancer cells and chemically treating them to induce an immune system response. The technology used to create the vaccines (called AC Vaccine) is licensed from Thomas Jefferson University. AVAX's lead vaccine candidate MVax is intended as a treatment for late-stage melanoma. The company is also developing vaccine candidates to fight ailments such as ovarian cancer (OVax) and non-small cell lung cancer (LungVax).
Business Summary  

AVAX Technologies, Inc., a development stage biotechnology company, together with its subsidiaries, engages in the development and future commercialization of individualized vaccine therapies and other technologies for the treatment of cancer in the United States and Europe. The company's autologous cell vaccine candidates include M-Vax under Phase III clinical status, which is used for the treatment of melanoma; L-Vax under Phase I-II clinical status that is used for the treatment of non-small cell lung cancer; and O-Vax under Phase I-II clinical status, which is used for the treatment of ovarian cancer. It also offers biological manufacturing services to other biotechnology and pharmaceutical companies; and contract manufacturing services in for cell and gene therapy, and biological products in France. AVAX Technologies, Inc. was founded in 1990 and is based in Philadelphia, Pennsylvania.


AVAX Technologies, Inc. Files Form 10 With SEC

Press Release Source: AVAX Technologies, Inc. On Friday February 4, 2011, 12:41 pm EST

PHILADELPHIA, Feb. 4, 2011 /PRNewswire/ -- AVAX Technologies, Inc. (Pink - News) ("AVAX" or the "Company") today announced that it filed a Form 10 with the Securities and Exchange Commission ("SEC").  Upon the effectiveness of this Form 10, AVAX will once again become a publicly reporting company.  The Company intends to seek to have its common stock trade on the Over-the-Counter Bulletin Board.

The Company's Form 10, which contains among other things, recent information about the Company's business, operations, financial results and capitalization, can be accessed through the website maintained by the SEC at

About AVAX Technologies, Inc.

AVAX Technologies, Inc. is a biotechnology company headquartered in Philadelphia, PA.   The Company is engaged in the research and clinical and commercial development of biological products and cancer therapeutics.

The Company's AC Vaccine platform is a therapeutic cancer vaccine.

Forward-Looking Statements

Certain statements in this release are "forward-looking" statements.   Forward-looking statements involve significant risks and uncertainties, and in light of the significant uncertainties inherent in such statements, the inclusion of such information should not be regarded as a representation by the Company that the objectives and plans of the Company will be achieved. In fact, actual results could differ materially from those contemplated by such forward-looking statements. These statements include, but are not limited to, the Company's immediate need to obtain additional funding to continue to finance the Company, the Company's plans, objectives, projections, expectations and intentions such as those relating to the future development of M-VAX® and its other vaccine candidates, as well as other important factors discussed in the Company's Form 10.   The Company does not undertake any obligation to release publicly any revisions to these forward-looking statements or to reflect the occurrence of unanticipated events. 


Press Releases & AVAX Information:

2/4/2001: AVAX Technologies, Inc. Files Form 10 With SEC

AVAX Announces Settlement Agreement with Cancer Treatment Centers of America and Approves $45 Million Private Placement Financing


Published: Aug 4, 2015 7:31 p.m. ET


PHILADELPHIA, Aug 04, 2015 (BUSINESS WIRE) -- AVAX Technologies, Inc., (“AVAX” or “The Company”) (AVXT – OTCMKTS), a leading developer of proprietary cancer immunotherapy products, has signed a Settlement & Release Agreement with Cancer Treatment Centers of America Inc. (“CTCA”) to positively resolve the existing debt obligations owed to CTCA.

Under the terms of the Settlement Agreement, CTCA has agreed to settle its $5,826,464.73 Judgment against AVAX in exchange for 860,000 Series A Convertible Preferred Shares at a consideration of $5.00 per share, and a one-time payment of $1.5 million in cash. Firebird Management, a shareholder and a creditor of AVAX, has agreed to swap its outstanding debt for the Series A Convertible Preferred Shares also at a consideration of $5.00 per share.

Andrew Dahl, AVAX Board Member noted, “we are extremely happy to be able to move forward with the reorganization of AVAX’s balance sheet and look forward to re-commencing the important planned clinical trials at AVAX. Our previous work with CTCA on clinical programs has been very successful.”

Richard Rainey, Acting Chief Executive Officer of AVAX, stated, “We are pleased that throughout the development of our AC Vaccine® platform, all of our data has remained consistently positive and has supported further development of the treatment. We feel our immunotherapy platform is consistent with recently approved products and could be additive to the benefits achieved in helping patients with cancer.”

SGC Canada Inc., is acting on behalf of AVAX with its creditors in negotiating its informal restructuring plan. David Holden, the Senior Corporate Advisor of SGC states that “AVAX will be effectively debt-free once the Financial Restructuring & Refinancing Plan is completed.” The Board of AVAX has previously approved the engagement of Phoenix Corporate Finance Inc., a corporate finance firm which specializes in alternative financing, to advise, structure, and facilitate the distribution of a proposed Private Placement financing. through select securities dealers in the US and Canada. AVAX intends to raise $45 million to fund its next round of clinical testing through the issuance of the Series A Convertible Preferred Shares.




  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
#1342  Sticky Note johnny canuck 01/26/16 07:32:21 PM
#1190  Sticky Note NEWS: HandyMan2000 10/19/15 08:52:59 AM
#1354   AVAX TECHS INCORPORATED (OTCMKTS:AVXT) Shorts Decreased by 56.14% katter 02/05/16 11:07:58 PM
#1353   Shorter on it today! Must need grocery/beer money johnny canuck 02/05/16 05:08:30 PM
#1352   "They" added a pretty graphic panel of biological...? katter 02/02/16 04:16:43 PM
#1351   Today was one screwy day with this stock..up, Geoman1 02/01/16 04:54:14 PM
#1350   What is going on with this? 5k share Jemmani 02/01/16 03:08:09 PM
#1349   Did you see who the testimonial is from? Adele STORMSHADOW44 02/01/16 08:01:43 AM
#1348   Uncomfortable feeling number two. katter 01/31/16 10:44:22 PM
#1347   Looks like new website coming. They took bayetta 01/31/16 02:22:40 PM
#1346   When I tried to tell my oncologist online katter 01/28/16 07:26:30 PM
#1345   Somewhat stunned by the little to no public Geoman1 01/27/16 04:44:05 PM
#1344   I think the original release was last Friday johnny canuck 01/27/16 07:24:22 AM
#1343   Was this Released Last Week Already? VMB-1 01/27/16 12:20:11 AM
#1342 johnny canuck 01/26/16 07:32:21 PM
#1341   Why don't you write directly to the new medimpact 01/25/16 06:36:27 PM
#1340   Well, they certainly did not shout out the Geoman1 01/25/16 05:13:14 PM
#1339   Someone keeps selling 5k at a time to Jemmani 01/25/16 02:53:16 PM
#1338   Just read the PR on the otcmarkets site... jesustrader 01/25/16 12:41:04 AM
#1337   @Katter: I wouldn't be so quick to give FiftyFifty 01/24/16 08:13:04 PM
#1336   Please be patient. Coming up from the mymovado1 01/24/16 06:20:11 PM
#1335   I looked on their website and this press katter 01/23/16 01:35:48 AM
#1334   Nice find. Thanks for posting. Time to load coco for cocoa puffs 01/22/16 06:26:10 PM
#1333   Found this on OTC board. mymovado1 01/22/16 10:47:28 AM
#1332   The owners and board members of AVXT surely Geoman1 01/19/16 04:19:24 PM
#1331   Feeling the same Bayetta....hurtful week on the big Geoman1 01/12/16 12:57:18 AM
#1330   Where are you pumpers now? All the bayetta 01/11/16 09:54:52 PM
#1328   I doubt it Katter.....Well, another face-kicking day on Geoman1 01/07/16 03:40:22 PM
#1327   Hopefully their PR department reads these posts full katter 01/06/16 01:02:43 AM
#1326   Agreed. hope they get the trial data johnny canuck 01/05/16 11:04:29 PM
#1325   Well, I do hope they do show up Geoman1 01/05/16 10:58:14 PM
#1324   Yea, but now they're looking for partners and $$$$$$ johnny canuck 01/05/16 10:30:37 PM
#1323   Lets see if they even show up. bayetta 01/05/16 10:19:37 PM
#1322   That's why I said the 8th would be johnny canuck 01/05/16 04:00:40 PM
#1321   wondering of the OVAX info will be released Geoman1 01/05/16 03:11:15 PM
#1320   1+ bayetta 01/04/16 10:42:05 PM
#1319   MYMO, Biotech showcase is Jan 11 to 14. johnny canuck 01/04/16 09:54:43 PM
#1318   Share price base is going up. 3 mymovado1 01/04/16 07:12:02 PM
#1317   a face-kicking day on the big boards today....ouch! Geoman1 01/04/16 02:34:26 PM
#1316   Looks like someone getting out????? johnny canuck 01/04/16 12:39:15 PM
#1315   Yup, about $4K bought. Must be a bayetta 12/29/15 10:29:32 PM
#1314   147k shares bought at .03. Could be a Jemmani 12/29/15 12:31:35 PM
#1313   Wow!! Nice slappage!! Rookiemove 12/29/15 11:31:21 AM
#1312   300,000 bid at .02. Money being moved in? Jemmani 12/28/15 09:33:58 AM
#1311   It was not an article. It was a Geoman1 12/22/15 01:13:31 PM
#1310   I did not find a recent "boom" article, katter 12/22/15 11:07:58 AM
#1309   can you cut and paste the write up? johnny canuck 12/21/15 04:49:43 PM
#1308   Pennystocks Weekly...AVXT...Biotech stock to "Boom"...interesting call by them.. Geoman1 12/21/15 04:04:55 PM
#1307   Why should it go up. Too much bayetta 12/20/15 01:08:19 AM
#1306   Now WITF won't this stock price go up? coco for cocoa puffs 12/18/15 03:27:27 PM
#1305   GD = acronym for "god damn". coco for cocoa puffs 12/18/15 03:25:59 PM
#1304   could posters write things out so others can katter 12/18/15 01:51:33 AM